| Title |
Marker antibodies in scleroderma and polymyositis: Clinical associations
|
|---|---|
| Published in |
Clinical Rheumatology, June 1989
|
| DOI | 10.1007/bf02030079 |
| Pubmed ID | |
| Authors |
D. J. De Rooij, L. B. A. Van De Putte, W. J. Habets, W. J. Van Venrooij |
| Abstract |
Sera of 34 patients with progressive systemic sclerosis and of 11 patients with polymyositis/dermatomyositis (PM/DM) were analyzed by the immunoblotting technique for the presence of marker antibodies. The presence of anti-centromere, anti-Topoisomerase-I (anti-Topo-I) and anti-Jo-1 antibodies was found to be highly specific for the CREST syndrome, diffuse scleroderma and PM/DM, respectively, but only of limited sensitivity (78, 44 and 45%, respectively). Anti-Topo-I positive diffuse scleroderma patients had a more severe disease (digital pitting scars and renal insufficiency) than anti-Topo-I negative diffuse scleroderma patients. Anti-Jo-1 was associated with interstitial lung disease. Longitudinal studies showed a constant antibody pattern. Our results confirm the clinical usefulness of these marker antibodies. |
Mendeley readers
The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 13% |
| Unknown | 7 | 88% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 38% |
| Student > Ph. D. Student | 1 | 13% |
| Student > Bachelor | 1 | 13% |
| Professor > Associate Professor | 1 | 13% |
| Unknown | 2 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 50% |
| Agricultural and Biological Sciences | 1 | 13% |
| Social Sciences | 1 | 13% |
| Engineering | 1 | 13% |
| Unknown | 1 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 July 2015.
All research outputs
#7,453,827
of 22,787,797 outputs
Outputs from Clinical Rheumatology
#1,139
of 2,993 outputs
Outputs of similar age
#4,165
of 14,882 outputs
Outputs of similar age from Clinical Rheumatology
#2
of 4 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,993 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 14,882 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.